Sign in Subscribe
Cardiology

Medicure Inc. Initiates Development of New Cardiovascular Product

Strategic Insights

— 1 min read

Medicure Inc. has announced the initiation of a development program for a new drug combining MC-1 and an angiotensin receptor blocker (ARB), targeting the treatment of hypertension in patients with metabolic syndrome. This debilitating condition affects approximately 50 million adults in the United States, according to the American Heart Association. The new product, MC-4262, aims to address the significant cardiovascular risk associated with metabolic syndrome.

Key Takeaways:

  • Medicure Inc. has initiated a development program for a new drug, MC-4262, combining MC-1 and an angiotensin receptor blocker (ARB) to treat hypertension in patients with metabolic syndrome.
  • The American Heart Association estimates that approximately one-quarter of adults in the United States, close to 50 million people, have metabolic syndrome.
  • The development of MC-4262 is a response to the growing need for effective treatments of hypertension in patients with metabolic syndrome, which carries a significant cardiovascular risk.
  • MC-4262 is expected to be a unique and cost-effective product, offering the advantages of MC-1 in combination with drugs from the largest classes of cardiovascular medications.
  • Sales of angiotensin receptor blockers (ARB's) in the United States were approximately USD$3.5 billion in 2003, representing a growth of over 20% compared to 2002 (IMS data).
  • Medicure's other combination product, MC-4232, combines MC-1 and an ACE inhibitor, targeting the growing diabetic hypertensive patient population.
  • The ongoing phase II MATCHED clinical study will provide critical data for the development of MC-4232 and the new ARB combination product.

Statistics:

  • Approximately 50 million adults in the United States have metabolic syndrome, according to the American Heart Association.
  • Sales of angiotensin receptor blockers (ARB's) were approximately USD$3.5 billion in 2003 in the United States, representing a growth of over 20% compared to 2002 (IMS data).
  • The USD$3 billion market in the United States for ACE inhibitors is expected to benefit from the development of Medicure's combination product, MC-4232.

Sources:

  • (NewsRx.com & NewsRx.net)
  • Albert D. Friesen, PhD, Medicure's president and CEO
  • American Heart Association
  • Yves Lacourciere, MD, FRCP, FACP, Director of the Hypertension Research Unit, Centre Hospitalier de l'Universite Laval, Quebec
  • Heart Disease Weekly via NewsRx.com & NewsRx.net (Copyright 2004)

Read more